Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001875620-25-000021
Filing Date
2025-08-13
Accepted
2025-08-13 11:17:42
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 12645
2 JOINT FILING STATEMENT jointfilingstatementscvp.htm EX-1 5263
  Complete submission text file 0001875620-25-000021.txt   19712
Mailing Address 1000 N. WEST STREET, SUITE 1200 WILMINGTON DE 19801
Business Address 1000 N. WEST STREET, SUITE 1200 WILMINGTON DE 19801 (302) 295-3800
Inhibikase Therapeutics, Inc. (Subject) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92155 | Film No.: 251209652
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O SANDS CAPITAL ALTERNATIVES, LLC 1000 WILSON BOULEVARD, SUITE 3000 ARLINGTON VA 22209
Business Address C/O SANDS CAPITAL ALTERNATIVES, LLC 1000 WILSON BOULEVARD, SUITE 3000 ARLINGTON VA 22209 703-562-4000
Sands Capital Life Sciences Pulse Fund II, L.P. (Filed by) CIK: 0001875620 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9
Type: SCHEDULE 13G/A